SCHEMBL2033165

SCHEMBL2033165

O=C(O)CCCNC(=O)c1ccccc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.73
NPC1 O15118 1/20 0.66
RAB9A P51151 1/20 0.66
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
HDAC3 O15379 3/20 0.64
HDAC4 P56524 3/20 0.64
HDAC1 Q13547 3/20 0.64
HDAC7 Q8WUI4 3/20 0.64
HDAC2 Q92769 3/20 0.64
HDAC10 Q969S8 3/20 0.64
HDAC11 Q96DB2 3/20 0.64
HDAC8 Q9BY41 3/20 0.64
HDAC6 Q9UBN7 3/20 0.64
HDAC9 Q9UKV0 3/20 0.64
HDAC5 Q9UQL6 3/20 0.64
NAAA Q02083 1/20 0.64
CYP1A2 P05177 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL950223 0.94 MAPK1 (0.83) MAPK1NPC1RAB9ACA1CA2
SCHEMBL1231651 0.93 MAPK1 (0.86) MAPK1NPC1RAB9AHDAC3HDAC4
SCHEMBL5655215 0.93 MAPK1 (0.86) MAPK1NPC1RAB9AHDAC3HDAC4
SCHEMBL10659200 0.93 MAPK1 (0.86) MAPK1NPC1RAB9AHDAC3HDAC4
SCHEMBL10865398 0.93 MAPK1 (0.86) MAPK1NPC1RAB9AHDAC3HDAC4
SCHEMBL9717451 0.92 MAPK1 (0.85) MAPK1CA1CA2CYP1A2CYP2C9
SCHEMBL11529762 0.90 PPARG (0.72) MAPK1NPC1RAB9ACA1CA2
SCHEMBL21320455 0.89 LMNA (0.70) MAPK1CA1CA2HDAC3HDAC4
Betamipron SCHEMBL4498475 0.88 PRSS1 (0.70) MAPK1NPC1RAB9ACA1CA2
Betamipron SCHEMBL605899 0.88 PRSS1 (0.70) MAPK1NPC1RAB9ACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113450-A1 Agent for Preventing and Alleviating Wrinkles SHISEIDO COMPANY LTD. (JP) 2010-05-06 US claimed
EP-2123253-A1 WRINKLING-PREVENTING AND -MODIFYING AGENT Shiseido Company, Ltd. (JP) 2009-11-25 EP claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-0576603-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN MERCK & CO. INC. (US) 1994-01-05 EP claimed
WO-1992016213-A1 PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN MERCK & CO., INC. (US) 1992-10-01 WO claimed
CN-119977829-A Quick synthesis method of beta-amino acid derivative 华南理工大学 2025-05-13 CN disclosed
US-20220007684-A1 APPLICATION OF ACYLATED DERIVATIVE OF AMINO ACID IN PREPARATION OF ANIMAL FEED ADDITIVE Anipha Technologies Pty Ltd (AU) 2022-01-13 US disclosed
US-20220007684-A1 APPLICATION OF ACYLATED DERIVATIVE OF AMINO ACID IN PREPARATION OF ANIMAL FEED ADDITIVE Anipha Technologies Pty Ltd (AU) 2022-01-13 US disclosed
EP-3878287-A1 APPLICATION OF ACYLATED DERIVATIVE OF AMINO ACID IN PREPARATION OF ANIMAL FEED ADDITIVE Peng, Xianfeng (CN) 2021-09-15 EP disclosed
EP-3878287-A1 APPLICATION OF ACYLATED DERIVATIVE OF AMINO ACID IN PREPARATION OF ANIMAL FEED ADDITIVE Peng, Xianfeng (CN) 2021-09-15 EP disclosed
CN-111629602-A Application of acylated derivative of amino acid in preparation of animal feed additive 黄华成 2020-09-04 CN disclosed
EP-2409569-B1 Method for administering GLP-1 molecules EMISPHERE TECH INC (US) 2017-08-16 EP disclosed
WO-1996018633-A1 ERYTHROMYCIN A 9-0-OXIME DERIVATIVES ENDOWED WITH ANTIBIOTIC ACTIVITY ZAMBON GROUP S.P.A. (IT) 1996-06-20 WO disclosed
CN-1116847-A N- (3-piperidinylcarbonyl) -beta-aminopropionic acid derivatives as PAF antagonists FUJISAWA PHARMACEUTICAL CO (JP) 1996-02-14 CN disclosed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP disclosed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US disclosed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP disclosed
US-4267174-A AND PROCESS FOR ADMINISTERING BOEHRINGER MANNHEIM, GMBH (DE) 1981-05-12 US disclosed
US-4016287-A COSMETIC AND ANTIINFLAMMATORY BOEHRINGER INGELHEIM GMBH (DT) 1977-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113450-A1 Agent for Preventing and Alleviating Wrinkles GABRB1, GABRB2, GABBR1 MAPK1 2400/4885NPC1 3421/4885RAB9A 1831/4885
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL MAPK1 1165/4885NPC1 2838/4885RAB9A 2748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.